Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, and that is more or less 9.11 % above the present share price of $76.07.
Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the earliest quarter of 2021.
The analysts price targets range from a high of hundred one dolars to a low of sixty one dolars.
From the newest earnings report of its, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is actually $99.57 billion.
Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with 4 stars on a 0 5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It works through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The retail or Long Term Care segment has selling of prescription medications and assortment of general merchandise.
The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products and similar services, including medical, pharmacy, dental, behavioural health, healthcare management abilities. The Corporate segment involves in offering management as well as administrative services. The company was developed by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.